Skip to main content

Advertisement

SpringerLink
Log in

Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Purpose/introduction

Growing evidence suggests complex interplay between nonalcoholic fatty liver disease (NAFLD) and bone health. The present study’s aim was to examine the impact of metformin treatment on circulating osteoprotegerin (OPG) in patients with NAFLD, a population in which this relationship has not yet been studied.

Methods

In a randomized, placebo-controlled study, 63 patients with NAFLD were assigned to one of two groups: Group 1 received daily metformin; Group 2 received a placebo. Metabolic parameters, insulin resistance markers and OPG levels were examined at baseline and at the end of the study.

Results

In the placebo group, liver function and OPG levels did not change during the study. Among metformin-treated patients, significant declines in OPG and alkaline phosphatase were observed. CRP and ALT decreased marginally during the 4-month treatment period. While at baseline circulating OPG levels did not differ significantly between the groups, by the end of the study OPG was significantly lower in patients treated with metformin than in the placebo group (p < 0.0001). Delta OPG was significantly greater in the metformin group than the placebo group (p = 0.001). In the general linear model, metformin treatment was the only significant independent predictor of endpoint and delta OPG.

Conclusions

Metformin treatment was associated with a significant decrease in OPG levels in patients with NAFLD. The effect on OPG was associated with exposure to metformin per se.

Clinical trial registration number

NCT01084486.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Li M, Xu Y, Xu M, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab 2012;97:2033–2038

    Article  CAS  PubMed  Google Scholar 

  2. Pardee PE, Dunn W, Schwimmer JB. Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther 2012;35:248–254

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Moon SS, Lee YS, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 2012;42:423–429

  4. Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 2007;127:954–960

    Article  CAS  PubMed  Google Scholar 

  5. Chu CJ, Lu RH, Wang SS, et al. Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha. Hepatogastroenterology 2007;54:2099–2102

    CAS  PubMed  Google Scholar 

  6. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007;17:517–524

    Article  CAS  PubMed  Google Scholar 

  7. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001;83:70–83

    Article  CAS  PubMed  Google Scholar 

  8. Fernández-Real JM, Ortega F, Gómez-Ambrosi J, Salvador J, Frühbeck G, Ricart W. Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos Int 2010;21:2101–2107

    Article  PubMed  Google Scholar 

  9. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007;156:555–562

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Schoppet M, Preissner KT, Hofbauer LC. RANK Ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Tromb Vasc Biol 2002;22:549–553

    Article  CAS  Google Scholar 

  11. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192–1194

    Article  CAS  PubMed  Google Scholar 

  12. Browner WS, Lui L-Y, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631–637

    CAS  PubMed  Google Scholar 

  13. Pirgon O, Bilgin H, Tolu I, et al. Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2011;75:189–195

    Article  CAS  Google Scholar 

  14. Zhen D, Chen Y, Tang X. Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complications 2010;24(5):334–344

    Article  PubMed  Google Scholar 

  15. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011;60(9):1278–1284

    Article  CAS  PubMed  Google Scholar 

  16. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539–543

    PubMed  Google Scholar 

  17. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344–1350

    Article  CAS  PubMed  Google Scholar 

  18. Kraemer de Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006;29:1083–1089

    Article  Google Scholar 

  19. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabet Med 2003;29:6s44–6s52

    CAS  Google Scholar 

  20. Meaney E, Vela A, Samaniego V, Meaney A, Asbún J, Zempoalteca JC, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008;35(8):895–903

    Article  CAS  PubMed  Google Scholar 

  21. Syn WK, Choi SS, Liaskou E, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106–115

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, et al. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond) 2011;120:239–250

    Article  CAS  Google Scholar 

  23. Haukeland JW, Dahl TB, Yndestad A, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol 2012;166:503–510

    Article  CAS  PubMed  Google Scholar 

  24. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005;16:417–423

    Article  CAS  PubMed  Google Scholar 

  25. Oh KW, Rhee EJ, Lee WY, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf) 2005;62:92–89

    Article  CAS  Google Scholar 

  26. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162–3165

    CAS  PubMed  Google Scholar 

  27. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518–527

    Article  CAS  PubMed  Google Scholar 

  28. Fraher LJ, Watson PH, Kisiel M, Natale BV, Hodsman AB. Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH (1–34). J Bone Miner Res 2000;15(Suppl 1):S441

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Wolfson Medical Center, Tel Aviv, Israel

    Elena Sofer

  2. Endocrinology, Wolfson Medical Center, Tel Aviv, Israel

    Marina Shargorodsky

  3. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Marina Shargorodsky

Authors
  1. Elena Sofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marina Shargorodsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Shargorodsky.

Ethics declarations

Informed consent

The study was approved by the regional ethical committee, and all procedures were performed in accordance with the guidelines of the Declaration of Helsinki. Informed written consent was obtained from all the subjects before participation. The study has been registered in the ClinicalTrials.gov registry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sofer, E., Shargorodsky, M. Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease. Hepatol Int 10, 169–174 (2016). https://doi.org/10.1007/s12072-015-9649-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-015-9649-6

Keywords

Search

Navigation